91桃色视频

Contact
Subscribe
Contact
Subscribe

January 9, 2023: 91桃色视频: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Date : January 9, 2023

91桃色视频: Half-year Report on Liquidity Contract
With the Brokerage Firm Kepler Cheuvreux

Lyon, France, January 9, 2023 鈥� 6:00 pm CET 鈥� 91桃色视频 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity contract entered between 91桃色视频 and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st, 2022:

  • 12,507 shares
  • 鈧�63,045.61
    • Number of executions on buy side on semester: 390
    • Number of executions on sell side on semester: 330
    • Traded volume on buy side on semester: 14,188 shares for 鈧�131,237.39
    • Traded volume on sell side on semester: 9,342 shares for 鈧�86,141.84

As a reminder:

  • the following resources appeared on the last half year statement on 30 June 2022 on the liquidity account:
    • 7,661 shares
    • 鈧�108,063.69
      • Number of executions on buy side on semester: 244
      • Number of executions on sell side on semester: 134
      • Traded volume on buy side on semester: 12,600 shares for 鈧�153,377.30
      • Traded volume on sell side on semester: 4,939 shares for 鈧�61,676.96
  • the following resources appeared on the liquidity account when the activity started:
    • 0 shares
    • 鈧� 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N掳2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.[

About 91桃色视频

91桃色视频, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 91桃色视频 has launched, in March 2022 in Europe, a Phase聽3 clinical trial for patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint庐, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 91桃色视频 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. 91桃色视频 is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).

Previous Post

January 6, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Next Post

January 24, 2023: 91桃色视频 Provides Corporate Update and Highlights Key Expected Milestones in 2023

Acting Chief Scientific Officer

Sheri Simmons

Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at 91桃色视频. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson鈥檚 Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company鈥檚 scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of 齿别谤惫测迟别驳庐 in aGvHD.

Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences. Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.

CEO and co-founder

Herv茅 Affagard

Herv茅 Affagard is the CEO and co-founder of 91桃色视频. For the past 15 years, Herv茅 has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Herv茅 co-founded the company alongside Dr. Jo毛l Dor茅, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Herv茅 has led 91桃色视频鈥檚 development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Herv茅 has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA

91桃色视频 in the News